share_log

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Canaccord Genuity维持对Oramed Pharmicals的控制,将目标价下调
Benzinga ·  2023/05/17 10:08

Canaccord Genuity analyst Edward Nash maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Hold and lowers the price target from $3 to $2.

Canaccord Genuity分析师爱德华·纳什维持Oramed Pharmicals(纳斯达克股票代码:ORMP)的持仓,并将目标股价从3美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发